At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 512 enrolled
Drug / intervention
Erenumab +1 moredrug
Likely dose
Erenumab 140 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Comprehensive Assessment of Erenumab Efficacy in Subjects With High Frequency Episodic Migraine With at Least 1 Previously Failed Preventive Treatment: a Global, Double-blind, Placebo-controlled Phase 4 Study
In Brief
A Phase 4 clinical trial evaluating Erenumab and Placebo for Migraine. Completed, enrolled 512 participants across 91 sites in 9 countries.
Detailed Summary
The primary objective of this study is to evaluate the treatment benefit of erenumab on headache duration of at least moderate pain intensity.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMigraine
CountriesBulgaria, Czechia, Hungary, Italy, Poland, Portugal, Romania, Spain, United States
Collaborators--
Timeline
Phase 4CompletedFinished
2020202120222023202420252026
First PostedFeb 2020
Enrollment StartSep 2020
Primary CompletionOct 2023
TodayJul 2026
First PostedFeb 5, 2020
Enrollment StartSep 15, 2020
Primary CompletionOct 26, 2023
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 6.4 years ago
Interventions
Erenumabdrug
140 mg, 2 consecutive injections of 70 mg
Placebodrug
2 consecutive injections